Core Insights - The article emphasizes the importance of drug economics in evaluating not only drug prices but also the cost savings associated with medications, including their impact on hospitalization duration, patient experience, and reduction of side effects and complications [2]. Group 1: Drug Economics - Liu Guoen, the director of the Peking University Global Health Development Institute, calls for the advancement of drug economics in China, highlighting its urgency and significance [2]. - Drug economics should consider the comparative effectiveness and costs of prescription drugs against other medications, as well as their broader implications on healthcare costs [2]. Group 2: Awards and Recognition - The 19th China Pharmaceutical Development Award recognized five individuals with the "Special Contribution Award," including Liu Guoen for his pioneering research and policy contributions in drug economics [2][3]. - Liu Guoen has made significant contributions to the field, including serving as a deputy editor for major international journals and founding China's first official journal on drug economics [4]. Group 3: Policy and Research Contributions - Since 2011, Liu Guoen has been a member of the State Council's Medical Reform Expert Advisory Committee, contributing to national healthcare policy [5]. - Liu Guoen leads a team that is developing the "Planetary Health Axis System," an AI-based system aimed at tracking and assessing health metrics across various dimensions [6]. Group 4: Challenges in Drug Evaluation - Liu Guoen points out the need for improved quality in generic drugs and the challenges faced by innovative drugs due to insufficient real-world data during early market entry [6]. - He stresses the necessity for continuous innovation in drug economic evaluation methods and the active participation of researchers in policy discussions to promote sustainable healthcare development [6].

Group 1: Medical Insurance Development - The National Medical Insurance Administration emphasizes empowering the pharmaceutical industry and implementing measures to support high-quality development of innovative drugs [1][2] - By mid-2025, significant progress is expected in medical insurance, including an increase in the number of insured individuals under maternity insurance to 253 million and total maternity insurance benefits expenditure reaching 67.832 billion [1] - The meeting highlights the need for a comprehensive adjustment of the national medical insurance drug catalog and the establishment of a commercial health insurance innovative drug catalog [2] Group 2: Maternity Insurance and Long-term Care - The meeting encourages regions to include flexible employment workers, migrant workers, and new employment forms in maternity insurance coverage, while also exploring basic service packages for prenatal check-ups [3] - There is a push for the implementation of long-term care insurance, with a focus on planning and supporting long-term care services at the community level [3] - The meeting calls for the integration of long-term care services with commercial insurance products to enhance accessibility and suitability of care [3] Group 3: Digital Transformation in Medical Insurance - The meeting aims to transition the medical insurance system from passive payment to proactive empowerment, focusing on health investment rather than just disease compensation [3] - There is an emphasis on promoting research in disease prediction modeling, pharmacoeconomics, and disease attribution analysis in collaboration with medical institutions and research organizations [3] - The integration of technology in medical insurance is encouraged to foster new medical services, AI health management, and smart elderly care [3]

Core Insights - The article discusses the ongoing efforts in China to support innovative drugs while addressing the challenges of pricing and payment systems, particularly focusing on the introduction of the "Category C" drug list and its implications for commercial health insurance [1][2]. Group 1: Category C Drug List - The Category C drug list is set to be explored and formed by 2025, with the first version expected to be released within the year, aligning with adjustments to the national basic medical insurance drug list [1][2]. - Experts indicate that the timing for the implementation of the Category C list is still uncertain, and it will focus on drugs that are clinically needed, innovative, and priced higher than those covered by basic insurance [3][6]. - The Category C list aims to provide a new payment pathway for innovative drugs that exceed the current insurance payment limits but meet clinical needs [4][5]. Group 2: Commercial Health Insurance Drug List - The commercial health insurance drug list is being accelerated by the China Insurance Industry Association, aiming to create a comprehensive multi-tiered drug directory that includes drugs approved by domestic and international regulatory bodies [7][8]. - The initial draft of the A-series list has been circulated for industry feedback, focusing on specific drugs and their therapeutic indications, with a total of 2,619 drugs being considered [7]. - The commercial health insurance model differs from the Category C list as it is driven by market demand and user willingness to pay, allowing for a more flexible and diverse drug directory [8][9]. Group 3: Economic Evaluation and Pricing - The use of pharmacoeconomic evaluations is suggested to enhance the pricing and payment processes for innovative drugs, providing a scientific basis for negotiations between pharmaceutical companies and insurance departments [5][6]. - The current payment structure shows that in 2024, the market size for innovative drugs is projected to reach 162 billion yuan, with insurance covering only 44% of costs, indicating a significant reliance on out-of-pocket expenses [7].